UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy

Cancer research (Chicago, Ill.), 2008-07, Vol.68 (14), p.5878-5887

2008

Volltextzugriff (PDF)

Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma

Cancer discovery, 2019-12, Vol.9 (12), p.1686-1695

2019

Volltextzugriff (PDF)

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

Nature (London), 2013-09, Vol.501 (7466), p.232-236

2013

Volltextzugriff (PDF)

p21-Activated Kinase 2 Regulates Endothelial Development and Function through the Bmk1/Erk5 Pathway

Molecular and cellular biology, 2015-12, Vol.35 (23), p.3990-4005

2015

Volltextzugriff (PDF)

Targeting cancer with kinase inhibitors

The Journal of clinical investigation, 2015-05, Vol.125 (5), p.1780-1789

2015

Volltextzugriff (PDF)

Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells

Proceedings of the National Academy of Sciences - PNAS, 2011-04, Vol.108 (17), p.7177-7182

2011

Volltextzugriff (PDF)

Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents

The Journal of cell biology, 2008-10, Vol.183 (1), p.101-116

2008

Volltextzugriff (PDF)

ERK inhibition overcomes acquired resistance to MEK inhibitors

Molecular cancer therapeutics, 2012-05, Vol.11 (5), p.1143-1154

2012

Volltextzugriff (PDF)

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

Proceedings of the National Academy of Sciences - PNAS, 2009-10, Vol.106 (43), p.18351-18356

2009

Volltextzugriff (PDF)

Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors

PloS one, 2009-05, Vol.4 (5), p.e5717-e5717

2009

Volltextzugriff (PDF)

Glycogen Synthase Kinase-3: Properties, Functions, and Regulation

Chemical reviews, 2001-08, Vol.101 (8), p.2527-2540

2001

Volltextzugriff (PDF)

Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab

Clinical cancer research, 2009-06, Vol.15 (12), p.4147-4156

2009

Volltextzugriff (PDF)

Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition

Proceedings of the National Academy of Sciences - PNAS, 2013-11, Vol.110 (48), p.19426-19431

2013

Volltextzugriff (PDF)

Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer

Molecular cancer therapeutics, 2015-01, Vol.14 (1), p.40-47

2015

Volltextzugriff (PDF)

Inhibitors of p21-activated kinases (PAKs)

Journal of medicinal chemistry, 2015-01, Vol.58 (1), p.111-129

2015

Volltextzugriff (PDF)

Group I Paks as therapeutic targets in NF2-deficient meningioma

Oncotarget, 2015-02, Vol.6 (4), p.1981-1994

2015

Volltextzugriff (PDF)

Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes

PloS one, 2012-05, Vol.7 (5), p.e36402-e36402

2012

Volltextzugriff (PDF)

Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma

Gastro hep advances, 2023, Vol.2 (3), p.307-321

2023

Volltextzugriff (PDF)

Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions

Drug metabolism and disposition, 2012-05, Vol.40 (5), p.919-927

2012

Volltextzugriff (PDF)

Calmodulin in Action: Diversity in Target Recognition and Activation Mechanisms

Cell, 2002-03, Vol.108 (6), p.739-742

2002

Volltextzugriff (PDF)

PPM1H is a p27 phosphatase implicated in trastuzumab resistance

Cancer discovery, 2011-09, Vol.1 (4), p.326-337

2011

Volltextzugriff (PDF)

Characterization of Dual Substrate Binding Sites in the Homodimeric Structure of Escherichia coli mRNA Interferase MazF

Journal of molecular biology, 2006-03, Vol.357 (1), p.139-150

2006

Volltextzugriff (PDF)

Protein Kinase A Downregulation Delays the Development and Progression of Polycystic Kidney Disease

Journal of the American Society of Nephrology, 2022-06, Vol.33 (6), p.1087-1104

2022

Volltextzugriff (PDF)

1 – 25 von 81

Suche als RSS-Feed

Aktive Filter

ThemaMedical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(66)

Publikationsform

Sprache

Englisch
(81)

Erscheinungsjahr

n.n

Thema

Science & Technology
(52)
Life Sciences & Biomedicine
(43)
Humans
(34)
Animals
(28)
Mice
(20)
Oncology
(20)
Cell Line, Tumor
(19)
Female
(14)
Biochemistry & Molecular Biology
(13)
Protein Kinase Inhibitors - Pharmacology
(13)
P21-Activated Kinases - Metabolism
(12)
P21-Activated Kinases - Antagonists & Inhibitors
(11)
Pharmacology & Pharmacy
(11)
Apoptosis
(10)
Cell Biology
(10)
Signal Transduction
(10)
Signal Transduction - Drug Effects
(10)
Chemistry, Medicinal
(9)
Kinases
(9)
Apoptosis - Drug Effects
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

p21-Activated Kinase 2 Regulates Endothelial Development and Function through the Bmk1/Erk5 Pathway

Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events

Targeting cancer with kinase inhibitors

Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells

Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents

ERK inhibition overcomes acquired resistance to MEK inhibitors

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors

Glycogen Synthase Kinase-3: Properties, Functions, and Regulation

Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab

Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition

Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer

Inhibitors of p21-activated kinases (PAKs)

Group I Paks as therapeutic targets in NF2-deficient meningioma

Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes

Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma

Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions

Calmodulin in Action: Diversity in Target Recognition and Activation Mechanisms

PPM1H is a p27 phosphatase implicated in trastuzumab resistance

Characterization of Dual Substrate Binding Sites in the Homodimeric Structure of Escherichia coli mRNA Interferase MazF

Protein Kinase A Downregulation Delays the Development and Progression of Polycystic Kidney Disease

Aktive Filter

Suchergebnisse filtern